Study of THN391 eye injection for diabetic macular edema
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests an experimental eye injection called THN391 for people with diabetic macular edema, a condition that causes vision loss due to swelling in the back of the eye. The study aims to see if the treatment is safe and may help improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with diabetic macular edema
- You have vision loss in the eye being treated
- You are not pregnant or breastfeeding
- You have not had eye surgery in the study eye in the last 3 months
- You have no other eye condition that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This study tests an investigational drug called SNP318 for people with diabetic macular edema (DME), a condition that causes swelling in the retina and can lead to vision loss. The goal is to see if SNP318 is safe and can improve vision.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.